To include your compound in the COVID-19 Resource Center, submit it here.

PTAB invalidates Zytiga patent

In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board invalidated all 20 claims of U.S. Patent No. 8,822,438 covering prostate cancer drug Zytiga abiraterone acetate from

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE